Ondine Biomedical suspends trading after Steriwave cuts infections 40.5% in phase III trial
AI Summary- Ondine Biomedical suspended trading to raise new investment for Steriwave.
- 40.5% was the reduction in surgical site infections during the phase III trial.
- Steriwave is a nasal disinfection product whose trial results were described as successful.